Australia Clears Kimberly‑Clark’s Kenvue Acquisition With Carefree, Stayfree Divestment Mandate

Australia’s competition regulator, the Australian Competition and Consumer Commission (ACCC), has approved Kimberly‑Clark’s proposed acquisition of Kenvue—Johnson & Johnson’s consumer health spin‑off—on the condition that the Carefree and Stayfree brands be divested in the Australian market. This regulatory green light, granted earlier this week, represents a crucial step forward in the deal’s global approval process.

The ACCC’s decision, announced on September 2, 2026, permits the transaction to progress in Australia but insists on the divestiture of the Carefree and Stayfree period care brands to preserve local market competition. This conditional approval brings Kimberly‑Clark closer to completing the multibillion‑dollar acquisition, which had previously faced scrutiny from other regulators. Some regulatory authorities have already approved the deal without imposing such conditions. The Australian ruling is significant because it identifies specific competition concerns tied to these brands in the Australian market.

Separately, Kimberly‑Clark confirmed it will webcast its presentation at the Barclays 19th Annual Global Consumer Staples Conference on September 9, featuring CEO Mike Hsu, president and COO Russ Torres, and CFO Nelson Urdaneta. This event will provide investors with live insights into the company’s strategic execution amid the Kenvue integration process.

Why It Matters

This conditional approval from the ACCC marks a material regulatory milestone for Kimberly‑Clark’s acquisition of Kenvue. It ensures the transaction can proceed in Australia, while requiring divestitures that may reshape Kimberly‑Clark’s portfolio in that market. The outcome of these divestitures—and how the company plans to comply—will be closely watched by investors as it could affect the long-term value and synergies expected from the acquisition.

The scheduled Barclays conference webcast offers a timely opportunity for management to address evolving investor questions around the Kenvue deal, its expected close by year-end, and how the divestiture requirement in Australia might influence the overall integration strategy.

Investors and analysts should monitor subsequent developments, especially any announcements detailing how Kimberly‑Clark will divest the mandated brands and the timeline for doing so. The company’s strategic planning for compliance and integration will inform expectations for post‑deal performance.